i-body Platform

i-body technology represents a class of humanised single-domain antibodies built on a human scaffold inspired by shark IgNAR antibodies. i-bodies feature an extended binding loop — up to twice the length of that in human antibodies — allowing them to access deep, hidden grooves and cavities that conventional antibodies cannot reach. With a molecular weight of only ~12 kDa, i-bodies combine the high specificity of monoclonal antibodies with the flexibility and tissue penetration of small molecules.
Their stability, solubility, and modularity make them ideal candidates for targeting complex antigens, including GPCRs, ion channels, and conserved pathogen epitopes.

IgNAR Platform

Our IgNAR platform leverages fully synthetic shark antibody repertoires to discover new single-domain binders directly from nature’s most resilient immune system. These molecules offer unique stability and adaptability in extreme conditions, forming the foundation for the development of novel humanised variants such as i-bodies.

Peptide Display Platform

The peptide platform expands our discovery toolkit to include high-affinity cyclic and linear peptides that complement antibody-based binders. These peptides are engineered for precision targeting and can serve as scaffolds for drug conjugation, diagnostics, or as complementary molecules in multi-target therapeutic strategies.

Together, these platforms create a versatile discovery engine capable of generating potent, long-acting biologics to combat infectious and immune-driven diseases.